Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.34 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.34 |
| ▸ | ACR | P10323 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31067680 | 0.98 | PLA2G10 (0.40) | PLA2G10SCN9AMAP2K4CDK8CDK19 | |
| Hydrochloric Acid SCHEMBL29825482 | 0.98 | PLA2G10 (0.40) | PLA2G10SCN9AMAP2K4CDK8CDK19 | |
| SCHEMBL27233000 | 0.85 | PLA2G10 (0.39) | PLA2G10SCN9AMAP2K4CDK8CDK19 | |
| SCHEMBL3452780 | 0.82 | DYRK1A (0.34) | CES2ALPLSNCA | |
| SCHEMBL1498674 | 0.82 | ALPL (0.46) | ALPL | |
| Hydrochloric Acid SCHEMBL31067451 | 0.81 | ALPL (0.45) | ALPL | |
| SCHEMBL2658376 | 0.81 | PLA2G10 (0.44) | PLA2G10SCN9AMAP2K4CDK8ACR | |
| SCHEMBL27316081 | 0.81 | MAPK1 (0.34) | CES2PIM1ALPLSNCA | |
| SCHEMBL27364050 | 0.77 | HCAR3 (0.34) | KMT2AALPL | |
| SCHEMBL1498628 | 0.77 | MAPK1 (0.59) | HTTALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | claimed |
| US-20210369742-A1 | METHODS OF TREATING THROMBOSIS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-12-02 | — | — | US | claimed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | claimed |
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | claimed |
| CN-107848971-A | Heterocyclic compound | 武田药品工业株式会社 | 2018-03-27 | — | — | CN | claimed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | claimed |
| CN-103930109-B | The substituted heterocyclyl amides of N- | NOVARTIS AG (CH) | 2016-11-30 | — | — | CN | claimed |
| US-9056867-B2 | N-substituted heterocyclyl carboxamides | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | claimed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | claimed |
| EP-2755652-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | Novartis AG (CH) | 2014-07-23 | — | — | EP | claimed |
| CN-103930109-A | N-substituted heterocyclyl carboxamides | NOVARTIS AG | 2014-07-16 | — | — | CN | claimed |
| WO-2013038390-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | claimed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12337005-B2 | Methods of treating thrombosis | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-118290357-A | Heterocyclic compounds useful in the treatment of disease | 艾匹根生物技术有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-1555364-A | Insecticidal diamides | �Ű˾ | 2004-12-15 | — | — | CN | disclosed |
| CN-1543460-A | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests | ��Ļ���Ű˾ | 2004-11-03 | — | — | CN | disclosed |
| CN-1541063-A | Method for controlling particular insects by applying anthranilamide compounds | ��Ļ���Ű˾ | 2004-10-27 | — | — | CN | disclosed |
| WO-2004067528-A1 | CYANO ANTHRANILAMIDE INSECTICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PLA2G10 694/4885SCN9A 2066/4885MAP2K4 1880/4885 |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | CFTR, AQP1, BDKRB1 | PLA2G10 3009/4885SCN9A 428/4885MAP2K4 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.